Angioedema

Angioedema - most related articles:

- Complete response letter for Cinryze for hereditary angioedema - 5.3
- Kalbitor, ecallantide, approved for treating hereditary angioedema - 4.7
- HPV vaccine's hypersensitivity reactions are rare - 2.2
- 35 new drugs approved in 2011 in US - 2.1

Angioedema articles

Kalbitor, ecallantide, approved for treating hereditary angioedema
The U.S. Food and Drug Administration approved Kalbitor (ecallantide) to treat sudden and potentially life-threatening fluid buildup that can occur in people with a rare genetic condition known as hereditary angioedema (HAE).

Complete response letter for Cinryze for hereditary angioedema
ViroPharma Incorporated (Nasdaq: VPHM) announced that it has received a Complete Response letter from the U.S. Food and Drug Administration (FDA) related to its supplemental Biologics License Application (sBLA) for Cinryze(TM) (C1 esterase inhibitor [human]) as a treatment for acute attacks of hereditary angioedema (HAE).

2 Angioedema articles listed above.


Mission
Health Newstrack is dedicated to serve recent and updated health & medical research, events/news, views/reviews to its subscribers and free access to general public, health & medical professionals, and other health seekers worldwide online with a user-friendly system.

List health news, Health organizations, Health news world, Glossary, Best health articles, Featured     Go to top

The information provided on Health Newstrack is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician. We comply with the HONcode principles for trustworthy health information, and Health News Track is hon code accredited, verify here.
About us, Site map Privacy policy, Disclaimer
© 2007, 2008, 2009, 2010, 2011 HealthNewsTrack.com
2.76